DHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Danaher's Accounts Payable for the quarter that ended in Mar. 2024 was $1,679 Mil.
Danaher's quarterly Accounts Payable declined from Sep. 2023 ($1,894 Mil) to Dec. 2023 ($1,766 Mil) and declined from Dec. 2023 ($1,766 Mil) to Mar. 2024 ($1,679 Mil).
Danaher's annual Accounts Payable declined from Dec. 2021 ($2,569 Mil) to Dec. 2022 ($1,856 Mil) and declined from Dec. 2022 ($1,856 Mil) to Dec. 2023 ($1,766 Mil).
The historical data trend for Danaher's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Accounts Payable | Get a 7-Day Free Trial |
![]() |
![]() |
1,515.00 | 2,049.00 | 2,569.00 | 1,856.00 | 1,766.00 |
Danaher Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Payable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2,081.00 | 1,956.00 | 1,894.00 | 1,766.00 | 1,679.00 |
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Thank you for viewing the detailed overview of Danaher's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Jose-carlos Gutierrez-ramos | officer: SVP, Chief Scientific Officer | C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
Linda Filler | director | 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037 |
Daniel Raskas | officer: VP-Corporate Development | 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006 |
Teri List | director | 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037 |
Joakim Weidemanis | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037 |
Walter G Lohr | director | DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006 |
Georgeann Couchara | officer: SVP, Human Resources | 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037 |
Raymond C Stevens | director | 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037 |
Matthew Mcgrew | officer: EVP & Chief Financial Officer | 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010 |
Jennifer Honeycutt | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037 |
Alan G Spoon | director | 1150 15TH ST NW, WASHINGTON DC 20071 |
Rainer Blair | officer: Executive Vice President | 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037 |
Feroz Dewan | director | C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003 |
Mitchell P Rales | director, officer: Chairman of Exec. Committee | 11790 GLEN ROAD, POTOMAC MD 20854 |
Brian W Ellis | officer: Senior Vice President - GC | 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.